Niemann-Pick Type C Disease - Pipeline Insight, 2021
SKU ID :DEL-19044460 | Published Date: 01-Sep-2021 | No. of pages: 60Description
TOC
Introduction
Executive Summary
Niemann-Pick Type C Disease: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Preregistration)
• Comparative Analysis
Arimoclomol: Orphazyme
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
IB1001: IntraBio
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Research programme: Niemann-Pick disease gene therapies - Sarepta Therapeutics/StrideBio
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Niemann-Pick Type C Disease Key Companies
Niemann-Pick Type C Disease Key Products
Niemann-Pick Type C Disease- Unmet Needs
Niemann-Pick Type C Disease- Market Drivers and Barriers
Niemann-Pick Type C Disease- Future Perspectives and Conclusion
Niemann-Pick Type C Disease Analyst Views
Niemann-Pick Type C Disease Key Companies
Appendix
Tables & Figures
Table 1 Total Products for Niemann-Pick Type C Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Companies
• Mandos LLC
• Cyclo Therapeutics
• Orphazyme
• IntraBio Inc
• Synaptogenix
• Evox Therapeutics
• SOM Biotech
• Sarepta Therapeutics/StrideBio
• ENDECE
• Amicus Therapeutics
- PRICE
-
$1500$4500